Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.GlobeNewsWire • Tuesday
Structure Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewsWire • 08/26/24
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts sayMarket Watch • 08/26/24
Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss FieldSeeking Alpha • 08/23/24
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?Zacks Investment Research • 07/24/24
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.The Motley Fool • 07/22/24
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?The Motley Fool • 06/11/24
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?The Motley Fool • 06/09/24
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary SharesGlobeNewsWire • 06/07/24
Structure Therapeutics Announces Pricing of Upsized $476 Million Public OfferingGlobeNewsWire • 06/05/24
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded WarrantsGlobeNewsWire • 06/03/24
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug ResultsInvestors Business Daily • 06/03/24
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290GlobeNewsWire • 06/03/24